medigraphic.com
Colegio de Medicina Interna de México.

2008, Número 1

<< Anterior Siguiente >>

Med Int Mex 2008; 24 (1)


Perspectiva histórica y aspectos epidemiológicos de la enfermedad de Parkinson

García S, Sauri SS, Meza DE, Lucino CJ

Idioma: Español
Referencias bibliográficas: 58
Paginas: 28-37
Archivo PDF: 286.25 Kb.


RESUMEN

La enfermedad de Parkinson es un padecimiento neurodegenerativo, progresivo y sin tratamiento curativo hasta el momento. En esta investigación se hace una revisión sobre lo más relevante de los aspectos histórico y epidemiológico de la enfermedad, sobre todo en los factores de riesgo y protectores reconocidos. Se consultaron las bases de datos MedLine y PubMed, desde enero de 1970 hasta julio de 2007, los criterios: Parkinson disease, PD, parkinsonism, epidemiology, cohort study, prevalence, incidence, risk factors, pesticide, diet, coffee, smoking, alcohol, inflammation, susceptibility genes, mortality, dementia y prognosis, se eligieron las publicaciones metodológicamente más sólidas y en especial metanálisis, además los aspectos históricos se consultaron en el buscador Google. Se encontró suficiente e importante información para lograr los objetivos de esta publicación.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Siderowf A. Parkinson’s disease: clinical features, epidemiology and genetics. Neurol Clin 2001;19(3):565-78.

  2. De Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s Disease. J Neurol Neurosurg Psychiatry 1997;62(1):10-5.

  3. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis inparkinsonism — a prospective study. Can J Neurol Sci 1991;18:275-8.

  4. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 1993;50(2):140-8.

  5. Jendroska K, Olasode BJ, Daniel SE, et al. Incidental Lewy body disease in black Africans. Lancet 1994;344(8926):882- 3.

  6. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52(6):1214-20.

  7. Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Changing epidemiology of Parkinson’s disease in southwestern Finland. Neurology 1999;52(2):302-8.

  8. Albin RL. Parkinson’s disease: background, diagnosis, and initial management. Clin Geriatr Med 2006;22(4):735-51.

  9. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984;16(3):278-82.

  10. Wang YS, Shi YM, Wu ZY, He YX, Zhang BZ. Parkinson’s disease in China. Coordinational Group of Neuroepidemiology, PLA. Chin Med J (Engl) 1991;104(11):960-4.

  11. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 1995;142(8):820-7.

  12. Baldereschi M, Di Carlo A, Rocca WA, et al. Parkinson’s disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2000;55(9):1358-63.

  13. Chen RC, Chang SF, Su CL, et al. Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology 2001;57(9):1679-86.

  14. Benito-León J, Bermejo-Pareja F, Morales-González JM, et al. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology 2004;62(5):734-41.

  15. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 2004;63(7):1240-4.

  16. Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology 1988;38(7):1031-4.

  17. Trenkwalder C, Schwarz J, Gebhard J, et al. Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson’s disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol 1995;52(10):1017-22.

  18. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999;354(9192):1771-5.

  19. Moghal S, Rajput AH, D’Arcy C, Rajput R. Prevalence of movement disorders in elderly community residents. Neuroepidemiology 1994;13(4):175-8.

  20. Errea JM, Ara JR, Aibar C, de Pedro-Cuesta J. Prevalence of Parkinson’s disease in lower Aragon, Spain. Mov Disord 1999;14(4):596-604.

  21. Yanagisaw N. Natural history of Parkinson’s disease: From dopamine to multiple system involvement. Parkinsonism and Related Disorders 2006 (in press).

  22. Clarke CE. Does levodopa therapy delay death in Parkinson’s disease? A review of the evidence. Mov Disord 1995;10(3):250-6.

  23. Hely MA, Morris JG, Traficante R, et al. The Sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999;67(3):300-7.

  24. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson’s disease: Olmsted County project. Neurology 1993;43(10):1918-26.

  25. Phillips NJ, Reay J, Martyn CN. Validity of mortality data for Parkinson’s disease. J Epidemiol Community Health 1999;53((9):587-8.

  26. Maraganore DM, Anderson DW, Bower JH, McDonell SK, Rocca WA. Autopsy patterns for Parkinson‘s disease and related disorders in Olmsted County, Minnesota. Neurology 1999;53(6):1342-4.

  27. Poewe W. The Sydney multicentre study of Parkinson’s disease [editorial]. J Neurol Neurosurg Psychiatry 1999;67(3):280-1.

  28. Lang A, Lozano A. Parkinson´s Disease. First of two parts. N Engl J Med 1998;339(15):1044-53.

  29. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114(Pt 5):2283-301.

  30. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson’s disease. Brain 1996;119(Pt 2):585-91.

  31. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol 2006;5(6):525-35.

  32. Semchuk KM, Love EJ, Lee RG. Parkinson’s disease and exposure to agricultural work and pesticide chemicals. Neurology 1992;42(7):1328-35.

  33. Ben-Shlomo Y. How far are we in understanding the cause of Parkinson’s disease? J Neurol Neurosurg Psychiatry 1996;61(1):4-16.

  34. Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S. A metaanalysis of Parkinson’s disease and exposure to pesticides. Neurotoxicology 2000;21(4): 435-40.

  35. Petrovitch H, Ross GW, Abbott RD, et al. Plantation work and risk of Parkinson disease in a population-based longitudinal study. Arch Neurol 2002;59(11):1787-92.

  36. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 2000;3(12):1301-6.

  37. Greenamyre JT, Hastings TG. Biomedicine. Parkinson’sdivergent causes, convergent mechanisms. Science 2004;304((5674):1120-2.

  38. Lai BC, Marion SA, Teschke K, Tsui JK. Occupational and environmental risk factors for Parkinson’s disease. Parkinsonism Relat Disord 2002;8(5):297-309.

  39. Paganini-Hill A. Risk factors for Parkinson’s disease: the leisure world cohort study. Neuroepidemiology 2001;20(2):118-24.

  40. Hernán MA, Chen H, Schwarzschild MA, Ascherio A. Alcohol consumption and the incidence of Parkinson’s disease. Ann Neurol 2003;54(2):170-5.

  41. Fall PA, Fredrikson M, Axelson O, Granérus AK. Nutritional and occupational factors influencing the risk of Parkinson’s disease: a case-control study in southeastern Sweden. Mov Disord 1999;14(1):28-37.

  42. Jiménez-Jiménez FJ, Mateo D, Giménez-Roldán S. Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson’s disease: a case-control study. Mov Disord 1992;7(4):339-44.

  43. Stocchi F, Olanow CW. Neuroprotection in Parkinson’s disease: clinical trials. Ann Neurol 2003;53(suppl 3):S87-97.

  44. Zhang SM, Hernán MA, Chen H, Spiegelman D, Willett WC, Ascherio A. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 2002;59(8):1161-9.

  45. Farooqui AA, Horrocks LA. Lipid peroxides in the free radical pathophysiology of brain diseases. Cell Mol Neurobiol 1998;18(6):599-608.

  46. Rijk MC, Breteler MM, den Breeijen JH, et al. Dietary antioxidants and Parkinson disease: The Rotterdam Study. Arch Neurol 1997;54(6):762-5.

  47. Johnson CC, Gorell JM, Rybicki BA, Sanders K, Peterson EL. Adult nutrient intake as a risk factor for Parkinson’s disease. Int J Epidemiol 1999;28(6):1102-9.

  48. Youdim KA, Martin A, Joseph JA. Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci 2000;18(4-5): 383-99.

  49. Anderson C, Checkoway H, Franklin GM, Beresford S, Smith-Weller T, Swanson PD. Dietary factors in Parkinson’s disease: the role of food groups and specific foods. Mov Disord 1999;14(1):21-27.

  50. Chen H, Zhang SM, Schwarzschild MA, et al. Folate intake and risk of Parkinson’s disease. Am J Epidemiol 2004;160(4):368-75.

  51. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson’s disease: false association or etiologic clue? Neurology 1995;45(6):1041-51.

  52. Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson’s disease. Am J Epidemiol 1994;139(12):1129-38.

  53. Hernán MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 2002;52(3):276-84.

  54. Hellenbrand W, Seidler A, Robra BP, et al. Smoking and Parkinson’s disease: a case-control study in Germany. Int J Epidemiol 1997;26(2):328-39.

  55. Quik M. Smoking, nicotine and Parkinson’s disease. Trends Neurosci 2004;27(9):561-8.

  56. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord 2004;10(suppl 1):S3-7.

  57. de Lau LM, Koudstaal PJ, van Meurs JB, Uitterlinden AG, Hofman A, Breteler MM. Methylenetetrahydrofolate reductase C677T genotype and PD. Ann Neurol 2005;57(6):927-30.

  58. van der Walt JM, Nicodemus KK, Martin ER, et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet 2003;72(4):804-11.




2020     |     www.medigraphic.com